Skip to main content


Gynecologic Cancer

A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared…
Study results support a lower starting dose of lenvatinib in clinical practice than what is currently recommended by…
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for…
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is…
First-line olaparib maintenance improves long-term PFS versus placebo for patients with newly diagnosed, advanced BRCA-…
In a real-world cohort of patients with BRCA-mutated relapsed epithelial ovarian cancer, efficacy and toxicity outcomes…
Findings from a recent study show better outcomes with PARP inhibitors over antiangiogenic agents for first-line…
The addition of veliparib to chemotherapy did not significantly impact health-related QoL in patients with stage III or…
Three speakers addressed issues relating to clinical pathways use in ovarian cancer.
Back to Top